1. Home
  2. LGHL vs VRAX Comparison

LGHL vs VRAX Comparison

Compare LGHL & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGHL

Lion Group Holding Ltd.

HOLD

Current Price

$0.68

Market Cap

862.9K

Sector

Finance

ML Signal

HOLD

Logo Virax Biolabs Group Limited

VRAX

Virax Biolabs Group Limited

HOLD

Current Price

$0.34

Market Cap

972.3K

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGHL
VRAX
Founded
2015
2013
Country
Singapore
United Kingdom
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
862.9K
972.3K
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
LGHL
VRAX
Price
$0.68
$0.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
408.6K
★ 565.2K
Earning Date
04-30-2024
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.10
52 Week High
$9.54
$13.19

Technical Indicators

Market Signals
Indicator
LGHL
VRAX
Relative Strength Index (RSI) 29.11 16.47
Support Level $0.58 $0.15
Resistance Level $1.13 $0.53
Average True Range (ATR) 0.34 0.18
MACD -0.04 -0.01
Stochastic Oscillator 3.97 3.16

Price Performance

Historical Comparison
LGHL
VRAX

About LGHL Lion Group Holding Ltd.

Lion Group Holding Ltd provides an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, and Over-The-Counter (OTC) stock options trading business. It offers these services through its all-in-one Lion Brokers Pro app and a variety of other apps available on iOS, Android, PC, and Mac platforms. The company's clients are mostly well-educated and affluent Chinese investors residing both inside and outside the PRC (excluding the United States). Its operating segments are: OTC Stock option trading, which generates maximum revenue, CFD trading, TRS trading, and Other. Geographically, the company derives maximum revenue from Hong Kong.

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

Share on Social Networks: